NINA NGO: Open Payments
NPI 1477212777 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,530 in 62 payments from 18 companies in 2025. Trend: 2023 $1,217 · 2024 $1,388 · 2025 $1,530
Food & beverage: $1,531
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $388 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $356 |
| ABBVIE INC. | 10 | $183 |
| Madrigal Pharmaceuticals | 2 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Gilead Sciences, Inc. | 3 | $60 |
| Lilly USA, LLC | 3 | $58 |
| PFIZER INC. | 2 | $48 |
| GENZYME CORPORATION | 2 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
Products named: TREMFYA, XIFAXAN, REZDIFFRA, RINVOQ, DUPIXENT, ENTYVIO, OMVOH, LINZESS.
Industry payments across PA — which companies pay providers there.
